AbbVie Gives Up On One Of Alector’s Alzheimer’s Candidates But Plenty More In Pipeline
Partners Still Working On Another Drug
Executive Summary
The major has terminated its deal with Alector for a SIGLEC-3 targeting Alzheimer’s candidate but is forging ahead with another novel drug covered by the firms’ collaboration in the challenging condition.